Perinatally Human Immunodeficiency Virus-Infected Adolescents and Young Adults Demonstrate Distinct BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Immunogenicity.

Autor:	Morrocchi E; Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy.; Precision Vaccines Program, Boston Children's Hospital, Boston, Massachusetts, USA., Pighi C; Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy., Pascucci GR; Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy.; Department of Systems Medicine, University of Rome 'Tor Vergata,' Rome, Italy., Cotugno N; Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy.; Department of Systems Medicine, University of Rome 'Tor Vergata,' Rome, Italy., Medri C; Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy., Amodio D; Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy., Colagrossi L; Department of Microbiology, Bambino Gesù Children's Hospital, Rome, Italy., Ruggiero A; Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy., Manno EC; Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy., Casamento Tumeo C; General Pediatrics Unit, Department of Emergency, Acceptance and General Pediatrics, Bambino Gesù Children's Hospital, Rome, Italy., Bernardi S; Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy., Smolen KK; Precision Vaccines Program, Boston Children's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Perno CF; Department of Microbiology, Bambino Gesù Children's Hospital, Rome, Italy., Ozonoff A; Precision Vaccines Program, Boston Children's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Rossi P; Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy., Levy O; Precision Vaccines Program, Boston Children's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA., Palma P; Academic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Italy.; Precision Vaccines Program, Boston Children's Hospital, Boston, Massachusetts, USA.; Department of Systems Medicine, University of Rome 'Tor Vergata,' Rome, Italy.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2022 Aug 15; Vol. 75 (Suppl 1), pp. S51-S60.
DOI:	10.1093/cid/ciac408
Abstrakt:	Background: Immunization of vulnerable populations with distinct immunity often results in suboptimal immunogenicity, durability, and efficacy. Methods: Safety and immunogenicity profiles of BNT162b2 messenger RNA coronavirus disease 2019 (COVID-19) vaccine, among people living with human immunodeficiency virus (HIV), were evaluated in 28 perinatally HIV-infected patients under antiretroviral therapy (ART) and 65 healthy controls (HCs) with no previous history of COVID-19. Thus, we measured severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral and CD4+ T cell responses. Samples were collected before vaccination (baseline, day [D] 0), at the second dose (D21), and at 4 weeks (D28) and 6 months (D180) after D0. Proteomic profiles at D0 and D28 were assessed with a multiplexed proximity extension assay (Olink) on plasma samples. Results: All HIV-infected patients mounted similar anti-SARS-CoV-2 humoral responses to those of HCs, albeit with lower titers of anti-trimeric S at D28 (P = .01). Only peripheral blood mononuclear cells of HIV-infected patients demonstrated at D28 an impaired ability to expand their specific (CD40L+) CD4+ T-cell populations. Similar humoral titers were maintained between the 2 groups at 6-months follow-up. We additionally correlated baseline protein levels to either humoral or cellular responses, identifying clusters of molecules involved in immune response regulation with inverse profiles between the 2 study groups. Conclusions: Responses of ART-treated HIV-infected patients, compared to those of HCs, were characterized by distinct features especially within the proteomic compartment, supporting their eligibility to an additional dose, similarly to the HC schedule. Competing Interests: Potential conflicts of interest . O. L. is a named inventor on patents relating to anti-infective proteins, vaccines adjuvants, and human assay platforms that model vaccine immunogenicity in vitro. O.L.has also received consulting fees from Moody’s analytics and funding from Boston Children’s Hospital Department of Pediatrics and the Hospital’s Chief Scientific Office. All other authors report no potential conflicts of interest. (© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu